The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.
 
Zeynep Eroglu
Consulting or Advisory Role - Array BioPharma; Compugen; Regeneron
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Tesaro
 
Ann Chen
No Relationships to Disclose
 
Jiannong Li
No Relationships to Disclose
 
Joseph Markowitz
Consulting or Advisory Role - Array Biopharma; Idera; Newlink Genetics
Research Funding - Genoptix (Inst); Macrogenics (Inst); Morphogenesis (Inst); Reata Pharmaceuticals (Inst)
 
Andrew Scott Brohl
Expert Testimony - GlaxoSmithKline (I)
 
Leticia Tetteh
No Relationships to Disclose
 
Adam Karpisek
No Relationships to Disclose
 
Hayley Taylor
No Relationships to Disclose
 
Jane Messina
No Relationships to Disclose
 
Vernon K. Sondak
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Castle Biosciences; EMD Serono; Genentech/Roche; Illumina; Merck/Schering Plough; Novartis; OncoSec; Pfizer; Polynoma; Sun Pharma
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Bellicum Pharmaceuticals; Mazor Robotics; Transenterix
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; HUYA Bioscience International; Immunocore; Merck; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Keiran Smalley
Research Funding - FORMA Therapeutics (Inst)